SCHEMBL6808565

SCHEMBL6808565

COc1cc2[nH]c(=O)[nH]c(=O)c2cc1-c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.65
KDM4E B2RXH2 5/20 0.65
HPGD P15428 4/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
KMT2A Q03164 2/20 0.60
MEN1 O00255 1/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
ATM Q13315 1/20 0.60
PDE3B Q13370 2/20 0.49
PDE3A Q14432 2/20 0.49
PDE2A O00408 1/20 0.47
IMPDH2 P12268 5/20 0.46
IMPDH1 P20839 1/20 0.46
PGR P06401 1/20 0.45
CA12 O43570 1/20 0.44
PARP1 P09874 1/20 0.44
CA9 Q16790 1/20 0.44
HSD17B10 Q99714 2/20 0.43
TNKS O95271 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2895978 0.80 KDM4E (1.00) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL16166753 0.77 KDM4E (0.75) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL24931754 0.77 KDM4E (0.75) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL6170426 0.76 KMT2A (0.71) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL7255463 0.76 CTSV (0.68) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL1943022 0.76 CTSV (0.68) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL28500138 0.74 KDM4E (0.75) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL10955203 0.74 ALDH1A1 (0.75) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL7807602 0.74 MEN1 (0.68) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A
SCHEMBL31611895 0.74 NPC1 (0.63) ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040034032-A1 Quinoline and quinazoline compounds useful in therapy PFIZER INC 2004-02-19 US disclosed
US-6649620-B2 Particularly in the treatment of benign prostatic hyperplasia. PFIZER INC. 2003-11-18 US disclosed
US-20030045525-A1 Quinoline and quinazoline compounds useful in therapy COLLIS ALAN JOHN (GB) 2003-03-06 US disclosed
EP-0875506-B1 Quinoline and quinazoline compounds useful in therapy PFIZER LTD (GB) 2003-02-26 EP disclosed
EP-0875506-A1 Quinoline and quinazoline compounds useful in therapy Pfizer Limited (GB) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045525-A1 Quinoline and quinazoline compounds useful in therapy NQO2, LPXN, BPHL ALDH1A1 670/4885KDM4E 3830/4885HPGD 402/4885
US-20040034032-A1 Quinoline and quinazoline compounds useful in therapy NQO2, LPXN, SDHA ALDH1A1 728/4885KDM4E 3783/4885HPGD 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.